Deep Lens Closes $14 Million Series A Financing to Further Advance Digital AI Pathology Platform for Clinical Trial Recruitment
Summary
Deep Lens will use the funding proceeds to further expand its artificial intelligence (AI) and platform product development activities and scale its service, sales, and marketing organizations to support current and anticipated demand and growth for its disruptive approach to clinical trial recruitment. “Since our inception, we’ve benefitted from a tremendous group of investors, which now includes the world class team at Northpond Ventures,” said Deep Lens co-founder and CEO Dave Billiter. Simon Arkell, president and co-founder added, “With this additional capital, we will move to quickly leverage our successes in the pathology industry and apply a highly disruptive approach to patient identification in clinical trials, one of the most expensive and time intensive issues faced by the pharmaceutical industry.” The VIPER platform and its unique distribution is a novel approach to the problem of patient recruitment in clinical trials," said Michael P. Rubin, M.D., Ph.D., founder and CEO at Northpond. In addition to providing essential workflow support to pathology teams, Deep Lens offers the most precise and timely source for identifying sites and patients for sponsored clinical trials.